Genome-wide association studies have identified significant association between polymorphisms of the Group 1B phospholipase A 2 (PLA2G1B) gene and central obesity in humans. Previous studies have shown that Pla2g1b inactivation decreases post-prandial lysophospholipid absorption, and as a consequence increases hepatic fatty acid oxidation and protects against diet-induced obesity and glucose intolerance in mice. The present study showed that transgenic mice with pancreatic acinar cell-specific overexpression of the human PLA2G1B gene gained significantly more weight and displayed elevated insulin resistance characteristics, such as impaired glucose tolerance, compared with wild-type (WT) mice, when challenged with a high-fat/carbohydrate diet. Pre-and post-prandial plasma b-hydroxybutyrate levels were also lower, indicative of decreased hepatic fatty acid oxidation, in the hypercaloric diet-fed PLA2G1B transgenic mice. These, along with earlier observations of Pla2g1b-null mice, document that Pla2g1b expression level is an important determinant of susceptibility to diet-induced obesity and diabetes, suggesting that the relationship between PLA2G1B polymorphisms and obesity may be due to differences in PLA2G1B expression levels between these individuals. The ability of pancreas-specific overexpression of PLA2G1B to promote obesity and glucose intolerance suggests that target phospholipase activity in the digestive tract with non-absorbable inhibitors should be considered as a therapeutic option for metabolic disease therapy.
Introduction
Genome-wide association studies have identified significant association (Po0.01) between PLA2G1B gene polymorphisms and central adiposity in humans. 1 This gene encodes the Group 1B phospholipase A 2 protein (PLA2G1B) that hydrolyzes the fatty acyl bond at the sn-2 position of phospholipids to generate free fatty acids and lysophospholipids. More recent lipidomic analyses of obesitydiscordant twins revealed that lysophosphatidylcholine elevation in plasma is a major obesity risk factor in humans. 2 Thus, the obesity differences in humans with PLA2G1B polymorphisms may involve PLA2G1B-mediated lysophospholipid production.
Our earlier studies with Pla2g1b À/À mice showed that the absence of Pla2g1b reduces post-prandial lysophospholipid levels because of decreased lysophospholipid absorption, but has no effect on absorption of other fat and fat-soluble nutrients. 3 Nevertheless, the Pla2g1b À/À mice are protected against obesity and insulin resistance induced by a high-fat/ carbohydrate diet. 4, 5 The reduction in lysophospholipid levels in Pla2g1b À/À mice increases post-prandial hepatic fatty acid oxidation, and, as a consequence, reduces fatty acid availability to extrahepatic tissues, resulting in obesity protection. 3 The reduced fatty acid availability also increases glucose utilization by extrahepatic tissues, thereby providing protection against glucose intolerance and diabetes. 5 These results suggest that PLA2G1B inhibition may be a novel therapeutic strategy for treatment of obesity and diabetes. The PLA2G1B gene is expressed primarily in the acinar cells of the pancreas, with less amounts of mRNA present in lung type II alveolar epithelial cells. 6, 7 The PLA2G1B protein is also present in insulin-secretory granules of pancreatic islet b-cells, and is secreted with insulin upon glucose stimulation. 8 The importance of pancreatic acinar cell-derived PLA2G1B versus enzymes synthesized in lung and islet b-cells toward diet-induced obesity and hyperglycemia has not been defined. This information is necessary to target PLA2G1B inhibitors to specific anatomic sites, where they can be effective in suppressing diet-induced obesity and diabetes, with minimal adverse effects. This study examined the impact of transgenic overexpression of the human PLA2G1B gene in mouse pancreatic acinar cells on diet-induced obesity and insulin resistance.
Materials and methods
Animals A 3.3-kB chimeric gene was constructed in the PUC13 vector by ligating a 508-bp DNA fragment containing the À500 to þ 8 region of the rat elastase-1 gene 9 to the 5 0 -untranslated region of the 2.2-kB human growth hormone (hGH) gene, followed by insertion of a 560-bp human PLA2G1B cDNA into the unique BamHI site at the 5 0 -untranslated region within exon 1 of the hGH gene ( Figure 1a ). The resulting chimeric gene containing the rat elastase-1 promoter and transcription initiation site, the PLA2G1B cDNA and the hGH gene with its accompanying introns, transcription termination and polyadenylation signal was excised from the plasmid vector, and then used to produce transgenic mice as described previously. 10 Founder mice were identified by PCR amplification of genomic DNA with hGH-specific primers, and mated with C57BL/6 mice for 10 generations to obtain transgenic mice in a congenic C57BL/6 background. Obesity and diabetes in PLA2G1B transgenic mice JG Cash et al react with both mouse and human Pla2g1b.
Pla2g1b
þ / þ and Pla2g1b À/À C57BL/6 mice were used as positive and negative controls, respectively.
Blood chemistry and glucose tolerance tests Blood was collected from the tail vein of mice after an overnight fast. Blood glucose level was determined with an Accu-Chek Glucometer (Roche Applied Science, Indianapolis, IN, USA). Insulin and b-hydroxybutyrate levels in plasma were measured by ELISA and colorimetric assay kits as described previously. 3 Glucose tolerance tests were conducted by measuring blood glucose levels before and at various time periods after feeding a bolus glucose-lipid mixed meal containing 50% glucose, 2.6 mM egg phosphatidylcholine, 13.33 mM triolein and 2.6 mM cholesterol. 5 Insulin sensitivity and resistance were estimated by homeostasis model assessment index, calculated as (fasting insulin concentration in mU ml À1 Â fasting glucose concentration in mmol l À1 )/22.5.
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Data analysis
All results are reported as means ± s.e., with the sample size as indicated. Significance (Po0.05) was evaluated using unpaired two-tailed Student's t-test assuming equal variance. All statistical analyses, including the Pearson correlation, were conducted using SigmaPlot 10.0 (Systat Software, San Jose, CA, USA).
Results
Western blot analysis of various tissues in wild-type (WT) and PLA2G1B transgenic mice showed increased PLA2G1B in pancreas, but not in the liver, lung, heart and muscle tissues of transgenic mice (Figure 1b) . Reverse transcriptase-PCR analysis of pancreatic mRNA isolated from the four independent transgenic mouse lines revealed different levels of human PLA2G1B expression, with the Tg-2 line showing the most robust expression level, whereas expression of the transgene in the Tg-4 line was minimal (Figure 1c ). Phospholipase A 2 enzymatic activities in the pancreas of transgenic mice were consistent with the mRNA expression data, with pancreas from Tg-2 mice displaying an B3.5-fold higher phospholipase A 2 activity, compared with nontransgenic WT mice, whereas enzymatic activities in the pancreas of the other three transgenic lines showed variable phospholipase A 2 activities that were not different from that observed in non-transgenic mouse pancreas (Figure 1d ). Initial characterization of the four transgenic mouse lines showed that the animals were healthy and breed normally with no obvious signs of distress. Plasma lipid levels and body weights were also similar between WT and PLA2G1B transgenic mice when they were maintained on a regular chow diet. In contrast, the Tg-2 PLA2G1B transgenic mice were significantly larger and gained more weight compared with WT and other lines of PLA2G1B transgenic mice when the animals were fed the hypercaloric high-fat/highcarbohydrate diet (Figure 2a) . Homeostasis model assessment of fasting plasma glucose and insulin levels revealed an accelerated rate of diet-induced insulin resistance in Tg-2 PLA2G1B transgenic mice (Figure 2b) . Glucose tolerance test administered to these animals 19 weeks after feeding them the hypercaloric diet also revealed delayed glucose excursion in PLAG1B transgenic mice (Figure 2c) .
Previous studies have shown improved glucose tolerance and obesity resistance in Pla2g1b-null mice because of elevated hepatic fatty acid oxidation as a consequence of reduced lysophospholipid absorption. 3 In the present study, plasma b-hydroxybutyrate levels, a surrogate measurement of hepatic fatty acid oxidation, 3 were significantly lower in Tg-2 PLA2G1B transgenic mice, compared with WT mice, under both fasting conditions and throughout a 3-h postprandial period after a fatty meal (Figure 2d ). Thus, reduced hepatic fatty acid oxidation may also account for the increase in diet-induced obesity and glucose intolerance in transgenic mice.
Discussion
Polymorphisms in the PLA2G1B gene associated with central obesity in humans are either polymorphisms in non-coding introns or synonymous base substitutions in exons, which do not result in sequence alterations of the PLA2G1B protein.
1 Therefore, the mechanism by which these PLA2G1B polymorphisms contribute to central obesity remains an enigma. The present study shows that overexpression of PLA2G1B in the pancreas reduces hepatic fatty acid oxidation and promotes diet-induced body weight gain and glucose intolerance. These results, together with our previous studies showing that decreased Pla2g1b activity is protective against diet-induced obesity and diabetes in mice, [3] [4] [5] 13 indicate that varying levels of PLA2G1B expression and activity in the digestive tract are an important determinant of susceptibility to diet-induced obesity and glucose intolerance. Thus, the association between PLA2G1B polymorphisms with obesity may be related to the PLA2G1B expression level in the pancreas. The contributory role of PLA2G1B in promoting diet-induced obesity and glucose intolerance suggests that pharmacological inhibition of its enzyme activity may be a viable strategy in the prevention of these metabolic disorders. In fact, we have shown in a proof-of-concept study that oral administration of a generic phospholipase A 2 inhibitor methyl indoxam effectively reduces plasma lysophospholipid levels and protects against diet-induced obesity and glucose intolerance in mice. 13 The bioavailability of orally fed methyl indoxam is B13% 13 and capable of inhibiting other phospholipases. 14 
Thus, methyl indoxam
Obesity and diabetes in PLA2G1B transgenic mice JG Cash et al may incur undesirable adverse effects in the system that limit its utility as a pharmacological inhibitor of PLA2G1B for obesity and diabetes intervention. The present study shows that specific elevation of PLA2G1B expression in pancreatic acinar cells is sufficient to reduce hepatic fatty acid oxidation and promotes diet-induced obesity and diabetes. These results suggest that development of nonabsorbable inhibitors, which specifically target PLA2G1B in the digestive tract, may be a safer and effective option for obesity and diabetes intervention. Obesity and diabetes in PLA2G1B transgenic mice JG Cash et al
